Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$49.4M Buy
371,000
+318,300
+604% +$36M 0.32% 45
2026
Q1
$5.87M Buy
52,700
+16,500
+46% +$1.95M 0.05% 392
2025
Q4
$4.88M Buy
+36,200
New +$3.95M 0.04% 478

Other funds holding ABVX

Michael Gelband's ABVX Position: Q2 2026 in Review

Michael Gelband reduced its Abivax (ABVX) stake by 78% in Q2 2026, selling an estimated $12.3M and leaving 31,209 shares worth $4.16M. The position accounts for 0.03% of the portfolio, ranked #557.

Michael Gelband first reported a position in ABVX in Q4 2025 and has held it in 3 quarters since. The position peaked at $29M in Q4 2025. 302 funds tracked by Wall St. Rank hold ABVX as of Q2 2026.

  • Michael Gelband held 31,209 shares of Abivax worth $4.16M as of Q2 2026.
  • Michael Gelband sold 109,053 Abivax shares in Q2 2026, an estimated $12.3M.
  • Abivax made up 0.03% of Michael Gelband's portfolio in Q2 2026, its #557 holding.
  • Michael Gelband first reported a position in Abivax in Q4 2025 and has held it in 3 quarters since.
  • Michael Gelband's Abivax position peaked at $29M in Q4 2025.
  • 302 funds tracked by Wall St. Rank held Abivax as of Q2 2026.

Based on ExodusPoint Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.